Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Q32 Bio Inc.
A maker of biologic medicines that calm an overactive immune system, Q32 Bio develops antibody treatments for autoimmune and inflammatory diseases. Its lead drug candidate, bempikibart, is being studied for alopecia areata, an autoimmune condition that causes hair loss. The Waltham, Massachusetts company began in 2017 as AdMIRx and renamed itself Q32 Bio in 2020 — a name it has never publicly explained.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
1.01 Entry into a Material Definitive Agreement · 3.02 Unregistered Sales of Equity Securities · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits